Posted by M.Popov on 12th Nov 2020
Trial size DLGAP5 antibodies available in the Antibody Validation Project
Trial size DLGAP5 antibodies available in the Antibody Validation Project
Introduction:
The DLG associated protein 5 is the protein encoded by the DLGAP5 gene and believed to play a role in cancerogenesis. Apart from that, this protein has a major role in regulating the adherens junction integrity and differentiation. On tissue level, it has cytoplasmic expression in several tissues, most abundant in most cell types in seminiferous ducts and in lymphoid cells and it can be used as a prognostic marker for unfavourable liver, pancreatic, endometrial and lung cancer. We provide a number of trial sized antibodies, which are suitable for DLGAP5 research purposes, and to help you make the right decision and find the best suited antibody for you, please find the answers to some of the key topics regarding DLGAP5 that we have provided in the links below.
- What is DLGAP5?
- Where is DLGAP5 found?
- What role does DLGAP5 play in disease?
- DLGAP5 antibodies in the Antibody Validation project
- Customer reviewed DLGAP5 antibodies
- Other DLGAP5 antibodies available in the Antibody Validation Project
- Popular DLGAP5 antibodies not currently in the Antibody Validation Project
- How does the Antibody Validation Project work?
What is DLGAP5?
The protein encoded by this gene is a potential cell cycle regulator that may play a role in carcinogenesis of cancer cells. Furthermore, it is a mitotic phosphoprotein regulated by the ubiquitin-proteasome pathway and a key regulator of adherens junction integrity and differentiation that may be involved in CDH1-mediated adhesion and signaling in epithelial cells.
Where is DLGAP5 found?
The DLGAP5 protein is mainly found in the centriolar satellite and cytosol of the cells and is not detected in the brain, but it is found in the T-reg cells of the immune system.
What role does DLGAP5 play in disease?
Having the ability to play a role in cancerogenesis, DLGAP5 has been found overexpressed in several human cancers, most noticeably in hepatocellular carcinoma. Furthermore, silencing of this gene by siRNA has been proven to significantly inhibits the proliferation and invasion of Hepatocellular Carcinoma cells(HCC).
DLGAP5 antibodies in the Antibody Validation project
St John's Laboratory offers a variety of trial size primary antibodies which target DLGAP5 , which are available to try through the Antibody Validation Project. Below we highlight those which have already been reviewed, as well as others which are available to try.
Customer reviewed DLGAP5 antibodies
| Model | Name | Host | Clonality | Rating | Application Tested |
|---|---|---|---|---|---|
| STJ93629 | Anti-HURP antibody | Rabbit | Polyclonal | 5 | WB |
Other DLGAP5 antibodies available in the Antibody Validation Project
Currently we do not have any other DLGAP5 antibodies available in the AVP.
Popular DLGAP5 antibodies not currently in the Antibody Validation Project
| Model | Name | Host | Clonality | Recommended Applications |
|---|---|---|---|---|
| STJ115536 | Anti-DLGAP5 Antibody | Rabbit | Polyclonal | WB,IF |
| STJ23390 | Anti-DLGAP5 Antibody | Rabbit | Polyclonal | WB,IF |
How does the Antibody Validation Project work?
In order to help our customers with their choice of antibody with low risk, we offer one of the largest ranges of primary antibodies with trial size options available.
The Antibody Validation Project works like this.
1. Order your trial size antibody online.
2. Explore its suitability.
3. Return your results by posting them on the product page.
4. Receive a sample refund.
Find out more here.